Stopping Wegovy / Zepbound / Ozempic: Rebound Weight Gain Evidence and Transition Planning

TL;DR — what to expect when stopping a GLP-1

Three large randomized trials — STEP-4 for semaglutide [1], the STEP-1 extension [3], and SURMOUNT-4 for tirzepatide [4] — have each measured what happens to body weight when Wegovy, Ozempic, or Zepbound is stopped after an active treatment period. The consistent finding: most patients regain a majority of lost weight within 12 months of discontinuation, even with continued lifestyle support.

The key numbers from primary-source PubMed-indexed publications verified for this article:

• STEP-4 (semaglutide): Patients who stopped semaglutide after a 20-week run-in (10.6% mean weight loss) regained a mean 6.9% body weight over the following 48 weeks. Those who continued semaglutide lost an additional 7.9%. Treatment difference: 14.8 percentage points (95% CI, −16.0 to −13.5; P<.001) [1].
• STEP-1 extension (semaglutide): One full year after the last semaglutide dose, participants had regained a mean 11.6 percentage points — approximately two-thirds of the 17.3% originally lost [3].
• SURMOUNT-4 (tirzepatide): Patients who stopped tirzepatide after a 36-week lead-in (20.9% mean weight loss) regained a mean 14.0 percentage points over the following 52 weeks. Only 16.6% maintained at least 80% of their lead-in weight loss vs 89.5% in the continuation arm [4].

The bottom line for clinical planning: stopping a GLP-1 is not the same as completing a course of antibiotics. The drug is treating a chronic condition (obesity), and when the treatment is withdrawn, the condition reasserts. This does not mean stopping is always wrong — there are legitimate reasons to stop (cost, pregnancy planning, intolerable side effects). But the evidence is unambiguous about what to expect, and that expectation should be built into the plan before stopping.

Medical disclaimer. This article summarizes published clinical trial data and FDA-label information for educational purposes only. It does not constitute medical advice. Do not stop, taper, or change any prescription medication without speaking with a licensed prescriber. Individual outcomes vary substantially.

STEP-4: the foundational discontinuation trial for semaglutide

The first trial designed specifically to answer the “what happens when you stop” question for semaglutide was STEP-4, published in JAMA on April 13, 2021 by Rubino and colleagues (PMID 33755728) [1]. STEP-4 was a randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites across 10 countries.

Trial design

The design was intentionally structured to isolate the effect of stopping the drug. All 902 participants first went through a 20-week run-in period on semaglutide (16 weeks of dose escalation to 2.4 mg weekly, plus 4 weeks at the maintenance dose). The point of the run-in was to ensure that everyone had already lost weight on the drug before the experiment started.

At week 20, 803 participants (89.0% of enrolled) had successfully reached the 2.4 mg/week maintenance dose. They were then randomized 2:1 — 535 to continue semaglutide at 2.4 mg weekly, 268 to switch to placebo. Both groups continued the same lifestyle intervention (counseling, exercise, calorie tracking) for the remaining 48 weeks. This was the critical control: both arms had the lifestyle piece; only one arm retained the drug.

At the point of randomization, the mean weight loss during the run-in was 10.6% of starting body weight (mean age 46 years; 79% women; mean body weight 107.2 kg) [1].

STEP-4 results: verbatim from PubMed abstract

The primary endpoint was percent change in body weight from week 20 (randomization) to week 68 (end of trial). The STEP-4 abstract (PMID 33755728) reports the following verbatim:

“With continued semaglutide, mean body weight change from week 20 to week 68 was −7.9% vs +6.9% with the switch to placebo (difference, −14.8 [95% CI, −16.0 to −13.5] percentage points; P < .001). Waist circumference (−9.7 cm [95% CI, −10.9 to −8.5 cm]), systolic blood pressure (−3.9 mm Hg [95% CI, −5.8 to −2.0 mm Hg]), and SF-36 physical functioning score (2.5 [95% CI, 1.6–3.3]) also improved with continued subcutaneous semaglutide vs placebo (all P < .001).”

Rubino et al., JAMA 2021 (PMID 33755728). Source: DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b (Wegovy prescribing information) Section 14 references this trial as the STEP 4 clinical study.

What the STEP-4 numbers mean in proportional terms

The placebo-switched participants had lost a mean 10.6% during the run-in, then regained 6.9 percentage points of body weight over the next 48 weeks of follow-up. That is approximately 65% of the weight they had lost — recovered within roughly 11 months of stopping the drug [1].

Meanwhile, the participants who continued semaglutide lost an additional 7.9% after already being on drug — ending the 68-week trial at a cumulative mean of approximately −17.4% from baseline. The gap between the two arms (14.8 percentage points) is the largest divergence ever recorded in a GLP-1 withdrawal trial.

Cardiometabolic effects also reversed

Weight was not the only variable that reversed in the placebo arm. STEP-4 also measured cardiometabolic secondary endpoints, and every improvement seen during the run-in — waist circumference reduction, blood pressure reduction, physical functioning improvement — diverged significantly between the two arms by week 68 [1]. The FDA-approved Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b) cites STEP-4 under Section 14 (Clinical Studies) as the foundational withdrawal evidence supporting the labeled indication.

One finding worth emphasizing for patients concerned about side effects on the continuation arm: gastrointestinal events were reported in 49.1% of continued-semaglutide participants vs. 26.1% in the placebo arm — but discontinuation rates due to adverse events were nearly identical (2.4% vs. 2.2%) [1]. The GI side effects did not drive meaningful dropout.

STEP-1 extension: what happens over a full year of discontinuation

STEP-4 measured 48 weeks post-randomization (equivalent to about 11 months from the last drug dose). The follow-up question — what happens after a full calendar year off the drug — was answered by a separate analysis of the STEP-1 cohort, published in Diabetes, Obesity and Metabolism in August 2022 by Wilding and colleagues (PMID 35441470) [3].

In the original STEP-1 trial [2], semaglutide 2.4 mg weekly produced a mean body weight loss of 17.3% (SD 9.3%) from baseline at week 68, versus 2.0% (SD 6.1%) on placebo. At week 68, treatment was discontinued in all participants and lifestyle intervention was also withdrawn. An off-treatment extension then tracked a representative subset for a further 52 weeks (through week 120).

Extension results: verbatim from PubMed abstract

“Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120. Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.”

Wilding et al., Diabetes Obes Metab 2022 (PMID 35441470) [3].

The “two-thirds regain” figure that appears throughout press coverage of GLP-1 discontinuation comes from this STEP-1 extension analysis [3], not from STEP-4 [1] (which measured a different outcome — the divergence between arms over 48 weeks, not the absolute regain). Both trials arrive at a similar conclusion (~65–67% of weight loss reversed), but the citation matters for accurate reporting.

The extension authors' conclusion in the published abstract is unambiguous: “Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health” [3].

SURMOUNT-4: tirzepatide-specific discontinuation evidence

Tirzepatide (Zepbound for weight management; Mounjaro for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist that produces meaningfully greater weight loss than semaglutide in head-to-head comparison (SURMOUNT-5, NEJM 2025). The withdrawal pattern, however, looks essentially the same.

SURMOUNT-4 (Aronne et al., JAMA 2024, PMID 38078870) [4] was a phase 3 randomized withdrawal trial conducted at 70 sites in 4 countries. The design followed a two-phase structure:

1. Lead-in phase (36 weeks, open-label): 783 participants received once-weekly subcutaneous tirzepatide at the maximum tolerated dose (10 or 15 mg) for 36 weeks. The mean weight loss during the lead-in was 20.9%.
2. Withdrawal phase (52 weeks, double-blind): 670 participants who completed the lead-in were randomized 1:1 to continue tirzepatide (n=335) or switch to placebo (n=335).

SURMOUNT-4 results: verbatim from PubMed abstract

“The mean percent weight change from week 36 to week 88 was −5.5% with tirzepatide vs 14.0% with placebo (difference, −19.4% [95% CI, −21.2% to −17.7%]; P < .001). Overall, 300 participants (89.5%) receiving tirzepatide at 88 weeks maintained at least 80% of the weight loss during the lead-in period compared with 16.6% receiving placebo (P < .001). The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo.”

Aronne et al., JAMA 2024 (PMID 38078870) [4]. The Zepbound prescribing information (DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) references Study 4 as the randomized withdrawal trial in Section 14 (Clinical Studies): “783 patients were treated with ZEPBOUND for up to 36 weeks, and 335 of these patients were treated for up to 88 weeks.”

The SURMOUNT-4 regain signal (+14.0 percentage points over 52 weeks) is substantially larger in absolute terms than the STEP-4 semaglutide signal (+6.9 percentage points over 48 weeks) — but this largely reflects the fact that tirzepatide started from a deeper loss (20.9% vs. 10.6%). In proportional terms, both drugs show roughly two-thirds of the lost weight returning within roughly a year of discontinuation.

The most striking single number from SURMOUNT-4: only 16.6% of patients who stopped tirzepatide maintained at least 80% of their lead-in weight loss — the majority did not [4].

Why does the weight come back? The mechanism

Understanding why regain happens is important for patient expectations and for planning. The mechanism has two interrelated components:

1. Appetite suppression is pharmacological, not curative

GLP-1 receptor agonists modulate appetite circuits in the arcuate nucleus of the hypothalamus — including the POMC/CART satiety neurons and the NPY/AgRP hunger neurons. The net clinical effect is a sustained downward shift in appetite set point: patients feel full faster, experience less “food noise” (intrusive thoughts about food between meals), and spontaneously reduce caloric intake without requiring conscious willpower.

When the drug is withdrawn, these central effects dissipate as blood levels fall. Semaglutide has a half-life of approximately one week; tirzepatide has a half-life of approximately five days. After the last weekly dose, drug levels drop below pharmacologically effective concentrations over one to three weeks. Patients describe the subjective experience as hunger “coming back” — specifically, return of the baseline appetite and food preoccupation that preceded treatment.

2. Homeostatic hormonal compensation

GLP-1s work partly by overriding the body's defended-weight system. Obesity involves a chronically dysregulated energy homeostasis: the body defends a higher-than-healthy weight set point via hormonal signals (elevated ghrelin, reduced leptin sensitivity, impaired satiety peptide signaling). The drug suppresses these signals pharmacologically. When the drug is removed, these compensatory signals reassert.

As fat stores begin to rebuild after discontinuation, leptin signaling shifts; ghrelin (the appetite-stimulating peptide secreted by the stomach) increases; and the downstream hypothalamic drive toward higher caloric intake increases. The system “wants” to return to its prior defended state. This is the same biology that explains why diet-and-exercise alone produces significant regain in the first 1-5 years after any calorie-restricted weight loss program — it is not unique to GLP-1s.

Clinical implication

The FDA-approved Wegovy (semaglutide) indication reads: “adjunct to a reduced calorie diet and increased physical activity for chronic weight management” — the word chronic is significant. The label frames the indication as chronic management, not a course of treatment. The STEP-4 and SURMOUNT-4 withdrawal data are the primary evidence base for why the indication is framed this way.

Timeline: appetite first, weight second

The sequence of events after stopping a GLP-1 follows a predictable pharmacological timeline. Understanding it helps patients distinguish between the drug wearing off (expected and normal) and an indication that something else is wrong.

The critical insight for patient counseling: appetite returns before visible weight does. The experience of heightened food preoccupation in the first few weeks after stopping is not a sign of failure or relapse — it is the expected pharmacological off-ramp. Patients who are prepared for this are better positioned to make deliberate behavioral choices during the high-risk window.

Can a slow taper prevent rebound?

This is one of the most common questions from patients who want to stop their GLP-1 but are trying to minimize regain. The honest answer is: no published randomized trial has tested a taper protocol for preventing weight rebound.

Both STEP-4 [1] and SURMOUNT-4 [4] measured abrupt discontinuation (participants switched directly to placebo at randomization). The STEP-1 extension [3] also followed abrupt discontinuation. None of these trials included a graduated dose-reduction arm. There is no controlled, published comparison of taper vs. abrupt stop for weight regain prevention.

The pharmacological argument for why tapering may not help: the weight regain after stopping a GLP-1 is not primarily driven by withdrawal rebound or a pharmacological overcorrection — it is driven by the absence of the drug's appetite-suppressive effect. Whether blood levels decline rapidly (abrupt stop) or more slowly (taper), once they fall below the threshold needed for appetite suppression, the appetite-regulating circuits return to their unmedicated state. A slower descent through ineffective blood levels may not meaningfully change the endpoint.

Some clinicians use interval extension as an informal taper — moving from weekly to every-10-day to every-two-week dosing. This effectively reduces the average dose and may smooth the transition, but no data support it as a weight-maintenance strategy. The tirzepatide microdosing evidence guide covers the published (and unpublished) literature on sub-maintenance dosing strategies.

Bottom line on tapering: there is no evidence-based taper protocol that prevents GLP-1 rebound weight gain. The goal of any stopping strategy should be either (1) maintaining some ongoing pharmacological treatment at a lower dose or (2) maximizing lifestyle infrastructure during and after the taper window.

Maintenance dosing: staying on a lower dose long-term

STEP-4 asked a binary question: continue vs. stop. It did not test lower-dose maintenance. But the biological implication of the STEP-4 finding is that continued treatment — even at reduced doses or extended intervals — is the most reliable strategy for maintaining weight loss, and that full discontinuation is the highest-risk option for regain.

What the FDA-approved label supports

The Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b) is silent on a lower-dose maintenance strategy. The approved maintenance dose is 2.4 mg once weekly. There is no FDA-approved “maintenance dose reduction” protocol comparable to, say, a steroid taper.

However, Section 14 of the Wegovy label's discussion of STEP-4 makes clear that ongoing treatment is expected to be long-term: the trial was designed to measure “weight loss maintenance” — not a finite course of therapy followed by discontinuation.

The cost barrier is the real issue for most patients

Most patients who stop their GLP-1 do not stop for biological reasons — they stop for cost reasons. The clinical decision to continue therapy long-term is straightforward when the biology is understood; the financial barrier is the harder problem.

Manufacturer self-pay programs as of May 2026:

• Wegovy (semaglutide 2.4 mg): NovoCare Savings Program — $299/month, no insurance required, all doses
• Zepbound (tirzepatide): LillyDirect — $299/month for vials (2.5 mg + 5 mg doses), $349/month (7.5 mg + 10 mg), $399/month (12.5 mg), $449/month (15 mg)
• Foundayo (orforglipron, oral GLP-1): LillyDirect — $149/month self-pay, no injection required; FDA-approved April 2026. Lower efficacy (~12.4% mean weight loss in ATTAIN-1 vs. ~14.9% semaglutide / ~20.9% tirzepatide) but the lowest-cost branded option. See Foundayo vs Zepbound dose and switch guide.

For patients who cannot sustain even $149-299/month, the conversation with the prescriber should include non-GLP-1 options — Qsymia (phentermine + topiramate ER), Contrave (naltrexone + bupropion ER), and Saxenda generic (liraglutide 3 mg, Teva biosimilar approved August 2025) — each of which is less effective than the newer GLP-1s but substantially cheaper.

Extended-interval dosing: limited but real data

Some prescribers have explored extending the dosing interval (e.g., weekly → every 10 days → every 14 days) as a cost-reduction strategy that preserves some pharmacological effect. This is not tested in the registration trials and does not have an FDA-approved protocol. The STEP-4 and SURMOUNT-4 data do not speak to this scenario — both used weekly dosing throughout. Patients exploring this should do so only under prescriber supervision, with explicit understanding that the evidence base is thin.

Lifestyle interventions: what actually holds the loss

Every trial in the STEP and SURMOUNT series provided lifestyle intervention (calorie counseling, exercise guidance, behavioral support) to both the drug and placebo arms. The STEP-1 extension [3] withdrew lifestyle support at week 68 alongside the drug. Despite this, a small fraction of patients in the semaglutide arm maintained substantial weight loss at week 120.

The question for any patient stopping a GLP-1 is: what lifestyle strategies give the best chance of holding the loss? The evidence-based answer is not encouraging for most people, but it is not zero:

Protein intake (1.6-2.2 g/kg body weight per day)

High-protein diets provide the strongest macronutrient-level satiety signal (via increased GLP-1, PYY, and CCK secretion), preserve lean mass during weight loss, and slow gastric emptying. After stopping a GLP-1, protein intake is the single most evidence-supported dietary strategy for maintaining the metabolic benefit of lean mass gained during treatment. Targets from exercise physiology research: 1.6-2.2 g/kg body weight per day, distributed across meals (at least 30 g per meal to maximally stimulate muscle protein synthesis).

Resistance training 2-3 times per week

GLP-1 therapy causes loss of both fat mass and lean mass — approximately 25-40% of the weight lost on semaglutide and tirzepatide is lean mass in the STEP and SURMOUNT DXA substudy analyses. Resistance training preserves lean mass, maintains resting metabolic rate, and provides ongoing appetite-regulation benefits independent of any medication. Structured resistance training 2-3 times per week is the most evidence-supported exercise modality for long-term weight maintenance.

Sleep (7-9 hours per night) and stress management

Chronic sleep restriction of even one to two hours per night increases ghrelin (appetite-stimulating) and reduces leptin (satiety-signaling), directly accelerating weight regain independent of medication status. Chronic psychological stress drives cortisol elevation, which promotes fat storage — particularly visceral fat — and increases cravings for hyperpalatable foods. Both are modifiable but often underaddressed in clinical weight-management discussions.

The realistic expectation

The consistent finding across the STEP and SURMOUNT discontinuation data is that lifestyle intervention alone — without ongoing pharmacological support — is insufficient for most patients to maintain GLP-1-level weight loss. This is not a judgment about individual effort or willpower; it reflects the defended-weight biology described in the mechanism section above. The clinical framing should be: lifestyle is necessary but not sufficient; the question for most patients is not “will lifestyle alone work?” but “which pharmacological support can I sustain long-term given my cost and preference constraints?”

What if I'm stopping because of cost?

Cost is the most common reason patients stop GLP-1 therapy. Before fully discontinuing, there are several conversation points worth raising with your prescriber:

1. Manufacturer savings programs (no insurance needed)

Both Novo Nordisk and Eli Lilly operate self-pay programs that substantially undercut retail pharmacy pricing. NovoCare for Wegovy: $299/month at all dose levels. LillyDirect for Zepbound: $299-449/month depending on dose. Neither requires insurance. These programs exist specifically because the manufacturers understand that cost drives discontinuation.

2. Switching to a lower-cost branded option

Foundayo (orforglipron) at $149/month is the lowest-cost FDA-approved GLP-1 in 2026. It is an oral daily pill (no injection, no refrigeration) with ~12.4% mean weight loss in the ATTAIN-1 trial. Patients who achieved 20%+ weight loss on Zepbound will not maintain that level on Foundayo — efficacy is lower — but Foundayo may hold more weight loss than full discontinuation. The Foundayo vs Zepbound switch guide has the re-titration details.

3. Compounded semaglutide or tirzepatide

As of May 2026, compounded semaglutide and tirzepatide from 503A patient-specific pharmacies remain legal under the FD&C Act despite the end of the FDA's shortage-based enforcement-discretion grace period (tirzepatide October 2024; semaglutide February 2025). Prices range from $99-300/month depending on the provider and dose. Before using any compounding pharmacy: verify NABP e-Profile accreditation, request the Certificate of Analysis (COA) for the active pharmaceutical ingredient lot, and confirm your prescriber is comfortable with the 503A designation. See our compounded tirzepatide vs compounded semaglutide guide.

4. Dose reduction as cost-reduction strategy

Discuss with your prescriber whether a lower maintenance dose (e.g., semaglutide 1.0 mg instead of 2.4 mg) could provide partial benefit at lower cost. This is off-label for the weight-management indication (which specifies 2.4 mg as the maintenance dose for Wegovy) and there is no randomized trial specifically comparing lower-dose maintenance outcomes after peak-dose weight loss. But it is a clinical conversation worth having before full discontinuation.

What if I'm stopping for pregnancy planning?

GLP-1 receptor agonists are contraindicated during pregnancy. Both FDA labels for the two weight-management GLP-1s (Wegovy and Zepbound) contain explicit pregnancy guidance.

Wegovy pregnancy guidance (verbatim FDA label)

The Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b) Section 8.3 states verbatim:

“Because of the potential for fetal harm, discontinue WEGOVY in patients at least 2 months before they plan to become pregnant.”

Section 8.1 of the Wegovy label further states:

“When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY in pregnant patients who are using it for weight reduction. Weight loss offers no benefit to a pregnant patient and may cause fetal harm.”

Zepbound pregnancy guidance (verbatim FDA label)

The Zepbound prescribing information (DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) Section 8.1 states:

“Weight loss offers no benefit to a pregnant patient and may cause fetal harm.” “Discontinue ZEPBOUND when a pregnancy is recognized.”

Washout period and fertility planning

The 2-month pre-pregnancy washout specified in the Wegovy label reflects semaglutide's pharmacokinetics: with a ~1-week half-life, drug levels become negligible within approximately 5 weeks; the 2-month window provides a margin. Tirzepatide has a slightly shorter half-life (~5 days) but the clinical guidance is similar: plan for at least 2 months off the drug before attempting conception.

A 2024 scoping review (Maslin et al., Clin Obes 2024, PMID 38951960) [5] confirmed that pregnancy during or shortly after GLP-1 treatment is contraindicated due to potential teratogenicity. The review noted that animal studies show fetal harm at exposures that overlap with therapeutic human doses; human data in pregnancy are limited because pregnant patients are excluded from all registration trials.

For patients on a GLP-1 who are planning pregnancy: discuss the timeline with both your prescriber and your OB-GYN. Weight regain during the washout period is likely (per the withdrawal data above). Some clinicians recommend establishing a stable, healthy pre-pregnancy weight before the washout begins, to give the best metabolic starting point for conception. GLP-1s are also being studied for PCOS and fertility outcomes — see our GLP-1, PCOS, and fertility: what the evidence shows.

What if I'm stopping for side effects?

Side effects — primarily gastrointestinal (nausea, vomiting, diarrhea, constipation) — are the second most common reason patients stop GLP-1 therapy. Before full discontinuation, there are often intermediate options:

Option 1: Dose hold, then re-titration from a lower step

GI side effects are most severe during dose escalation and typically resolve within 1-4 weeks as the patient accommodates. The Wegovy label Section 2.1 supports holding at a lower dose for an extended period before escalating, and returning to a lower dose after a missed period. A temporary dose hold or return to a prior dose step is often sufficient to make the drug tolerable.

Option 2: Switch from semaglutide to tirzepatide (or vice versa)

The two drug mechanisms overlap (both work on GLP-1 receptors) but tirzepatide also acts on GIP receptors. SURMOUNT-1 data showed lower absolute nausea rates for tirzepatide vs. semaglutide in cross-trial comparison (though cross-trial comparisons have known limitations). Some patients who cannot tolerate semaglutide find tirzepatide more manageable, and vice versa. See the tirzepatide vs semaglutide head-to-head comparison.

Option 3: Switch to oral GLP-1 (Foundayo)

Oral orforglipron (Foundayo) has a different pharmacokinetic profile than subcutaneous semaglutide or tirzepatide. GI side effect rates in the ATTAIN-1 trial were comparable to injectable GLP-1s in absolute percentage terms, but some patients who found injection-site or subcutaneous delivery-related side effects intolerable find oral administration more manageable.

Option 4: Non-GLP-1 weight-loss medications

Patients who cannot tolerate any GLP-1 have several FDA-approved non-GLP-1 options: Qsymia (phentermine + topiramate ER), Contrave (naltrexone + bupropion), Xenical/alli (orlistat), and Saxenda generic (liraglutide 3 mg). None achieve GLP-1-level weight loss on average, but they provide pharmacological support during the transition. See our GLP-1 side-effect Q&A hub and the Contrave evidence review for specifics.

What about bariatric surgery as a longer-term alternative?

Bariatric surgery is not an alternative to stopping a GLP-1 — it is a separate, more invasive intervention with its own risk-benefit profile. But it comes up frequently in discussions about sustainable long-term weight loss when GLP-1 cost or tolerability is a recurring barrier.

The key distinction: bariatric surgery produces durable weight loss that does not depend on ongoing medication cost or adherence. Roux-en-Y gastric bypass and sleeve gastrectomy produce mean weight losses of 25-35% over 1-2 years that are substantially maintained at 5-10 years in the majority of patients, without ongoing drug costs. This is mechanistically different from GLP-1 therapy: surgery anatomically alters gut physiology (GI anatomy, gut hormone release, gut microbiome), producing durable changes to appetite set point.

For patients who are repeatedly stopping and restarting GLP-1s due to cost, or who have lost and regained the same 30-50 lbs multiple times, the bariatric surgery discussion is worth having with a bariatric surgeon. Eligibility criteria under most insurance coverage: BMI ≥40, or BMI ≥35 with at least one weight-related comorbidity. Many patients on GLP-1s who meet these thresholds have never been offered a bariatric surgery consultation.

For a detailed comparison of GLP-1 and bariatric options see our bariatric surgery vs GLP-1 decision guide.

What to tell your prescriber before stopping

If you are considering stopping your GLP-1, the most productive prescriber conversation covers these four questions:

1. What is the reason I want to stop? Cost → explore savings programs, dose reduction, lower-cost alternatives. Pregnancy planning → discuss washout timeline with OB-GYN. Intolerable side effects → explore dose hold, switch, or non-GLP-1 alternatives. Already at goal weight → discuss maintenance dosing plan.
2. What is my realistic weight trajectory if I stop? Ask your prescriber to walk through the STEP-4 and SURMOUNT-4 numbers specifically — not to be discouraging, but to calibrate expectations and plan accordingly. If two-thirds regain is the average, what is the prescriber's plan for the six months after stopping?
3. Is there a lower-cost option that provides partial benefit? Foundayo at $149/month, extended Wegovy intervals, or compounded options through a verified 503A pharmacy may provide meaningful appetite suppression at substantially lower monthly cost than full-dose brand-name therapy.
4. What are the monitoring checkpoints? If stopping is the final decision, agree on follow-up appointments at 6 weeks, 3 months, and 6 months to track weight and decide whether to restart. Restarting a GLP-1 after regain is not a failure — it is the chronic disease management model in practice.

Do not stop any prescription medication without speaking to your prescriber. While GLP-1s do not cause a pharmacological withdrawal syndrome and stopping cold turkey is not dangerous, the clinical decision should include a plan for what comes next.

Related research

• GLP-1 plateau decision tree: compounded not working? — the companion article for weight loss that has slowed or stopped while still on therapy. Distinct from this article: plateau is on-drug stall; rebound is post-discontinuation.
• Life after GLP-1: maintenance dosing, microdosing, tapering & stopping decision hub — four-path decision framework covering maintenance at full dose, extended intervals, microdosing, and full discontinuation with regain expectations for each.
• Tirzepatide microdosing evidence guide — sub-maintenance tirzepatide dosing strategies, published case series, and the evidence (and absence of evidence) for each approach.
• Foundayo vs Zepbound switch and dose-equivalence guide — for patients considering a switch to oral GLP-1 instead of full discontinuation.
• GLP-1 side-effect Q&A hub — if side effects are the reason for stopping, this hub covers every common adverse reaction from the FDA labels and trial adverse-event tables.
• Insurance dropped your GLP-1? Appeal playbook — if insurance discontinuation is the forcing function, the four-phase appeal framework: internal appeal, external review, cash-pay bridge, switch strategy.
• Compounded tirzepatide vs compounded semaglutide — for patients who want to continue therapy at lower cost via compounding pharmacies; covers regulatory status, 503A rules, and pharmacy verification.
• What happens when you stop semaglutide? STEP-4 evidence — shorter companion article focused specifically on the STEP-4 and STEP-1 extension semaglutide data.